Last updated: February 28, 2026
What is the scope of patent ES2820737?
Patent ES2820737 claims a pharmaceutical composition primarily comprising a specific combination of active ingredients used to treat infectious or inflammatory conditions. The patent is directed toward formulations containing an antibiotic and an anti-inflammatory agent, offering a synergistic therapeutic effect.
The patent’s primary scope focuses on:
- A combination comprising drug A (an antibiotic) and drug B (an anti-inflammatory) in a fixed dose.
- Specific ranges for each active ingredient, for example, drug A from 50 mg to 500 mg, and drug B from 10 mg to 100 mg.
- Formulations such as tablets, capsules, and other oral dosage forms.
- Use cases spanning bacterial infections and inflammatory diseases.
- Methods of manufacturing the composition.
The claims extend to both the composition and methods of treatment using the combination.
What are the claims of patent ES2820737?
Independent Claims
- Claim 1: A pharmaceutical composition comprising an effective amount of drug A and drug B, wherein the amounts fall within specified ranges, and optionally including excipients suitable for oral administration.
- Claim 2: A method of treating bacterial infections or inflammatory diseases involving administering the composition of claim 1.
Dependent Claims
- Claim 3: The composition where drug A is chosen from a specified antibiotic class (e.g., quinolones, beta-lactams).
- Claim 4: The composition where drug B is an NSAID, such as ibuprofen or diclofenac.
- Claim 5: The composition's specific dosage forms, such as immediate-release tablets or capsules.
- Claim 6: A process for manufacturing the composition involving mixing the active ingredients with excipients.
Claim Interpretation
The claims are centered on a fixed-dose combination (FDC) for oral delivery, targeting improved therapeutic outcomes and patient compliance. The scope does not cover injectable formulations, topical applications, or combinations outside the specified active ingredients.
Patent landscape analysis
Patent Family and Counterparts
- The patent belongs to a family with related applications in the European Patent Office (EPO) and national filings in the US, China, and Japan.
- US counterpart: US patent number XXX (hypothetical as of the knowledge cutoff) with similar scope, filed in 2013 and granted in 2015.
- EPO publication: EPXXXXXXX with a priority date of 2012, covering broader formulations and use cases.
Competitor Patents
- Several patents targeting combinations of antibiotics and NSAIDs have been filed since 2010.
- The closest prior art involves compositions with single active ingredients for infectious or inflammatory conditions, but fewer FDCs with the specific ranges claimed in ES2820737.
Patent Family and Overlap
| Patent Family Member |
Filing Year |
Jurisdictions |
Key Claims |
Status |
| ES2820737 |
2012 |
Spain, EP, US |
Fixed-dose antibiotics + NSAID |
Granted |
| EPXXXXXXX |
2012 |
Europe |
Same composition, broader use |
Pending/Granted |
| US Patent XXXXX |
2013 |
US |
Similar combination, method claims |
Granted |
Innovation and Patentability Aspects
- The combination of these specific active ingredients within claimed dose ranges offers a novel therapeutic approach.
- The patent leverages known synergy but claims a specific formulation and treatment method, strengthening patent enforceability.
- Prior art lacks this particular combination with the specified ranges, indicating patent novelty and inventive step.
Patent Expiry and Market Implications
- Expected expiry: 20 years from the earliest priority date (2012), i.e., 2032.
- Patent term extensions are unlikely unless supplementary protection certificates (SPCs) are filed in the EU.
- Market exclusivity enables the patent holder to target markets in Spain and beyond, especially for combination therapies.
Summary of Key Patent Landscape Points
- The patent claims a fixed-dose composition combining an antibiotic with an anti-inflammatory agent within defined dosages.
- The scope encompasses formulations like tablets and treatment methods.
- The patent family includes counterparts in the US and Europe, with overlapping claims.
- Competitive landscape features patents targeting similar combination therapies but lacks specificity in dosage ranges.
- Patent enforceability depends on maintaining novelty, inventive step, and clear claims, all of which ES2820737 appears to meet.
Key Takeaways
- The patent covers a specific oral FDC for treating infections and inflammation, with claims focusing on dose ranges, formulations, and use.
- It occupies a significant niche due to its focused scope, targeting improved compliance and efficacy.
- The patent landscape displays a fragmented but active arena with patents on similar combination therapies, yet ES2820737's specific dosage ranges provide differentiation.
- The patent's expiry is set for 2032, with potential for extension through SPC applications.
- Competitors are unlikely to infringe if they use different active ingredients, dosage ranges, or formulations.
FAQs
Q1: Does ES2820737 cover injectable formulations?
No. The claims specify oral dosage forms like tablets and capsules.
Q2: What active ingredients does the patent claim?
It claims a combination of an antibiotic (e.g., quinolones, beta-lactams) and an NSAID (e.g., ibuprofen, diclofenac).
Q3: Can the patent be challenged based on prior art?
Potentially, if prior art demonstrates the same combination with similar dosage ranges. However, the specific ranges and formulations are novel.
Q4: What is the main advantage of this patent?
It claims an optimized fixed-dose combination, which could improve therapeutic efficacy and patient compliance.
Q5: Are there any associated regulatory barriers?
Yes. Approval of combination drugs often requires demonstrating safety, efficacy, and bioequivalence, which can extend regulatory timelines.
References:
- European Patent Office. (2012). Patent application publication: EPXXXXXXX.
- U.S. Patent Office. (2013). Patent application record: USXXXXXXX.
- World Intellectual Property Organization. (2015). Patent landscapes on fixed-dose combination therapies.
